Casirivimab / imdevimab Side Effects
Applies to casirivimab / imdevimab: parenteral solution concentrates for injection for iv infusion
The American Society of Health-System Pharmacists, Inc. represents that the information provided in the accompanying monograph was formulated with a reasonable standard of care, and in conformity with professional standards in the field. Readers are cautioned that a combined regimen of Casirivimab and Imdevimab is not an approved treatment for coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, but rather, is being investigated for and is currently available under an FDA emergency use authorization (EUA) for the treatment of mild to moderate COVID-19 in certain outpatients. The American Society of Health-System Pharmacists, Inc. makes no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to the information contained in the accompanying monograph, and specifically disclaims all such warranties. Readers of this information are advised that ASHP is not responsible for the continued currency of the information, for any errors or omissions, and/or for any consequences arising from the use of the information contained in the monograph in any and all practice settings. Readers are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and that the information contained in the monograph is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. The information contained in the monograph is not a substitute for medical care.
Side effects include:
Data from an ongoing trial in outpatients with mild to moderate COVID-19 (NCT04425629; R10933-10987-COV-2067) indicate serious adverse events reported in 1.6% of patients treated with casirivimab and imdevimab 2.4 g (1.2 g of each drug), 0.8% of patients treated with casirivimab and imdevimab 8 g (4 g of each drug), and 2.3% of patients in placebo group. Grade 3 or 4 adverse events reported in those who received the 2.4-g dose included pneumonia, hyperglycemia, nausea, and vomiting; none of these events were considered related to the drugs.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.